David Gerber, M.D. Professor Endowed Title David Bruton, Jr. Professorship in Clinical Cancer Research School Medical School Department Internal Medicine | Public Health You have reached the Academic Profile. For more information on the doctor and patient care, please visit the clinical profile. Biography David Gerber, M.D., is a Professor in the Department of Internal Medicine at UT Southwestern Medical Center, and a member of the Division of Hematology and Oncology. He serves as Co-Director of the Experimental Therapeutics Program. I’m invested in helping patients have a better quality of life. Originally from Chicago, Dr. Gerber holds a bachelor's degree in history from Yale University in New Haven, Connecticut, where he graduated cum laude. He earned his medical degree at Cornell University Medical College in New York and completed his internship and residency in internal medicine at UT Southwestern, where he served as Chief Resident. He then received advanced training through a fellowship in medical oncology at Johns Hopkins University School of Medicine in Baltimore. Certified by the American Board of Internal Medicine in medical oncology, Dr. Gerber joined the UT Southwestern faculty in 2007. Dr. Gerber is active in research related to lung cancer, including clinical trials. His research has generated more than 250 publications that he has authored or co-authored, including articles and book chapters. His studies have contributed to invitations to lecture both nationally and internationally. He serves on several committees at UT Southwestern. Beyond the institution, he serves as Chair of the Clinical Trials Advisory Committee for the Cancer Prevention and Research Institute of Texas (CPRIT) and is a member of the National Comprehensive Cancer Network (NCCN) Oncology Research Program Investigator Steering Committee. Dr. Gerber holds memberships in several professional organizations, and he has been honored with numerous awards, including being named a Best Doctor in Dallas by D Magazine during the years of 2011-2023. Education Medical School Weill Cornell Graduate School of Medical Science (2000) Residency UT Southwestern Medical Center (2004), Internal Medicine Fellowship Johns Hopkins Hospital (2007), Medical Oncology Research Interest Lung Cancer, Clinical and Translational Research Oncology Outcomes Publications Transferring care to enhance access to early-phase cancer clinical trials: Protocol to evaluate a novel program Nwachukwu C, Makhnoon S, Person M, Muthukrishnan M, Kazmi S, Anderson LD, Kaur G, Kapinos KA, Williams EL, Fatunde O, Sadeghi N, Robles F, Basey A, Hulsey T, Pruitt SL, Gerber DE Contemporary Clinical Trials Communications 2024 Jun 39 Resistance Mechanisms in ROS1-Positive Lung Cancer: New Insight into a Rare but Clinically Important Entity von Itzstein MS, Gerber DE Clinical chemistry 2024 Apr 70 571-573 Effect of Patient Navigation on Completion of Lung Cancer Screening in Vulnerable Populations Bhalla S, Natchimuthu V, Lee JL, Wahid U, Zhu H, Santini NO, Browning T, Hamann HA, Johnson DH, Chiu H, Craddock Lee SJ, Gerber DE JNCCN Journal of the National Comprehensive Cancer Network 2024 Apr 22 151-157 Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer Gerber DE, Wang Y, Ramalingam SS, Bhalla S, Sun Z, Borghaei H, Brahmer JR, Schiller J Oncologist 2024 Apr 29 342-349 The Joint Problem of Rheumatoid Arthritis and Lung Cancer Bermas BL, Gerber DE Journal of Thoracic Oncology 2024 Feb 19 196-198 Contemporary Trends in Reviewing Test Results Through the Electronic Patient Portal among Patients with Cancer Bhalla S, Prasad T, Xie D, Gerber DE JAMA Oncology 2024 Jan 10 139-140 Telemedicine and Cancer Clinical Research Opportunities for Transformation von Itzstein MS, Gwin ME, Gupta A, Gerber DE Cancer Journal 2024 Jan 30 22-26 Emerging Strategies in Lung Cancer Screening: Blood and Beyond Bhalla S, Yi S, Gerber DE Clinical chemistry 2024 Jan 70 60-67 Distinct autoantibody profiles across checkpoint inhibitor types and toxicities Mu-Mosley H, von Itzstein MS, Fattah F, Liu J, Zhu C, Xie Y, Wakeland EK, Park JY, Kahl BS, Diefenbach CS, Gerber DE OncoImmunology 2024 13 Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice von Itzstein MS, Yang Y, Wang Y, Hsiehchen D, Sheffield TY, Fattah F, Popat V, Ahmed M, Homsi J, Dowell JE, Rashdan S, Lohrey J, Hammers HJ, Hughes RS, Wang T, Xie Y, Gerber DE Frontiers in immunology 2024 15 Results 1-10 of 251 1 2 3 4 5 Next Last Books Featured Books Targeted Therapies for Non-Small Cell Lung Cancer David E. Gerber (2011). Oxford University Press Lung Cancer Apar K. Ganti, David E. Gerber (Ed.) (2014). Oxford University Press Honors & Awards National Cancer Institute(NCI) Director's Award (2023) Leaders in Clinical Excellence Mentoring AwardUT Southwestern (2022) Exceptional Research in Navigation AwardAcademy of Oncology Nurse & Patient Navigators (2018) National Cancer Institute (NCI)Midcareer Investigator Award in Patient-Oriented Research (2016) Top DoctorsCastle Connolly (2015-2023) Best Doctors in DallasD Magazine (2011-2023) Clinical Investigator Team Leadership AwardNational Cancer Institute (2011) Career Development AwardAmerican Society of Clinical Oncology (2009) Professional Associations/Affiliations American Society of Clinical Oncology Dallas County Medical Society Eastern Cooperative Oncology Group International Association for the Study of Lung Cancer Texas Medical Association
